CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

FDA-NDA215866 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA215866.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical
1

Critical

100%

0

High

0%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: MOUNJARO (TIRZEPATIDE) — Type 1 - New Molecular Entity

Policy FDA-NDA215866 · Endocrinology

Critical

Mounjaro (tirzepatide) is administered via subcutaneous injection, which typically places self-administered drugs under Medicare Part D rather than Part B — the 'Part B' billing pathway noted here war

View alert

Audit documentation

Building an audit file that includes FDA-NDA215866?

The Tripwire Audit Pack exports 12 months of Endocrinology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Endocrinology audit pack — $349One-time purchase · not a subscription